🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Really excited to take my kids out to vote today, especially for my daughter. Go vote!

🚨 #CardioNerds Podcast Alert! 🎙️ 🔍 Dive into a fascinating case: When "normal" cholesterol isn't so normal. Uncover an unusual presentation of Familial Hypercholesterolemia w/ the National Lipid Association team. 🌟 #FOAMed #Cardiology #Lipidology #FH #MedTwitter

Congratulations to the Ionis team! FDA approval for TRYNGOLZA (olezarsen). First FDA-approved therapy for FCS - exciting news for patients! ir.ionis.com/news-releases/…

High-intensity statins lower LDL cholesterol in high-risk ASCVD patients, but combining moderate-intensity statins with ezetimibe offers similar benefits with a lower risk of new-onset diabetes and statin intolerance. ja.ma/4gHAk5w 이용준

Knowledge is power! This #LpaAwarenessDay, explore the Top 🔟 recent Journal of Clinical Lipidology articles on Lp(a), chosen by NLA Executive Committee Member, Board Member, & Communications Council Chair, Marlys Koschinsky. Which article will you dive into?👇

A BIG moment just dropped: The design of the Lp(a)HORIZON trial is now published. sciencedirect.com/science/articl… Brief summary: 1- 8,323 patients 2- median Lp(a) level of 108 mg/dL and 236 nmol/L - higher than likely anticipated 3- 79% of patients were ≥90 mg/dL - higher than

The NIH Women’s Health Initiative enrolled 10,000's of participants in trials of medications & tracked health of thousands for 3+ decades. “This trial taught us an immense amount about prevention of disease in women." The Trump admin is cancelling it.science.org/content/articl…

We are searching for one more clinical research coordinator to join our team at the Penn Lipid Clinic. Dan Soffer Perfect for a recent graduate taking a gap year looking for more experience working with patients. Can start ASAP! Apply here: wd1.myworkdaysite.com/recruiting/upe…

“Only one in five patients on high-intensity statin monotherapy get to goal, so the need for combination therapy is inevitable,” Prof Kausik Ray FMedSci told TCTMD. Learn more about the new #JACC study: bit.ly/4lWOwLO

Exciting day with more obicetrapib data for at ⁦⁦European Atherosclerosis Society⁩ with publications in ⁦NEJM⁩ and ⁦The Lancet⁩ ⁦John Kastelein⁩ ⁦Prof Kausik Ray FMedSci⁩ ⁦Michael Davidson MD⁩ ⁦Adam Nelson⁩ ⁦Julie Butters⁩ ⁦Monash Victorian Heart Institute⁩ ⁦NewAmsterdam Pharma Corporation⁩

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details authors.elsevier.com/a/1l4pB2d9GI27…

When it rains, it pours - More OBI data. Across 3 phase 3 trials, BROADWAY (obi), BROOKLYN (obi) & TANDEM (obi + ezetimibe), obicetrapib, an oral CETP inhibitor, effectively reduced not only LDL-C, but also Lp(a), especially in those with moderately elevated Lp(a) levels. In

Congratulations Dan Soffer, a great mentor, colleague and friend, well-deserved! Sorry to have missed this part of NLA!

Florian Kronenberg, Magda Daccord, et al made this important & influential document fly: "The Brussels International Declaration on Lipoprotein(a) Testing and Management". Patients, politicians, clinicians & sceintists: MEASURE Lp(A) IN ALL! atherosclerosis-journal.com/article/S0021-… Open access

How does Obicetrapib lower LDL-C?🔬 At #NLASessions, we asked Archna Bajaj to break down her team's lipoprotein kinetic study and what it reveals about the drug's mechanism. Watch the video to learn more! #ClinicalTrial #LDLCholesterol #PennMedicine #Research

📉Lower LDL-C for longer is better. The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C. Read the guidelines & recommendations: lipidjournal.com/article/S1933-…. Beth Jackson Christie Ballantyne

Pelacarsen is the first potential medical therapy for targeting Lp(a) directly Our new review Journal of Clinical Lipidology describes its mechanism of action and evidence so far: lipidjournal.com/article/S1933-… Archna Bajaj UC San Diego Cardiology UC San Diego Cardiology Fellows National Lipid Association ASPC Family Heart Foundation